2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by CDC / Security Risk Solutions, Inc. (SRS). This guide is not an authorized publication; it is the continuous build for version 2022.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/security-rs/opioid-cds-r4/ and changes regularly. See the Directory of published versions

Home

Official URL: http://fhir.org/guides/cdc/opioid-cds/ImplementationGuide/fhir.cdc.opioid-cds-r4				Version: 2022.1.0
Active as of 2026-03-07				Computable Name: Opioid_CDC
Copyright/Legal: Centers for Disease Control and Prevention (CDC)

Introduction

This implementation guide (IG) provides resources and discussion in support of applying the Centers for Disease Control and Prevention (CDC) 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain, including support for the following guideline recommendations:

• Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration
• Recommendation #2 - Prioritize Nonopioid Pain Therapies
• Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy
• Recommendations #4 and #5 - Lowest Effective Dose
• Recommendation #6 - Prescribe Lowest Effective Dose and Duration
• Recommendation #7 - Opioid Therapy Risk Assessment
• Recommendation #8 - Naloxone Consideration
• Recommendation #9 - Consider Patient’s History of Controlled Substance Prescriptions
• Recommendation #10 - Urine Drug Testing
• Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines
• Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder

For further details on how the behaviors for the artifacts were determined, refer to the Process Documentation.

Background

This implementation guide was developed based on work initially done as part of the Clinical Quality Framework (CQF) Initiative, a public-private partnership sponsored by the Centers for Medicare & Medicaid Services (CMS) and the U.S. Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC), to identify, develop, and harmonize standards for clinical decision support and electronic clinical quality measurement, as well as a joint effort by the CDC and ASTP/ONC focused on improving processes for the development of standardized, shareable, computable decision support artifacts using the 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain as a model case.

Feedback and Discussion

Discussions on the use of this IG happen at the HL7 Clinical Decision Support (CDS) Workgroup. Feedback and contributions are welcome and can be raised with the CDS Workgroup or submitted directly using the New Issue link in the footer of every page.

Related IGs

CPG IG

This implementation guide has followed and applied the methodology laid out by the HL7 Clinical Practice Guideline (CPG) IG. The CPG IG offers an abstract high-level methodology for translating clinical guidelines into electronic Clinical Decision Support (eCDS) artifacts based on the following steps:

• Select: Select content and recommendations for implementation
• Represent: Apply selected recommendations to the implementation approach
• Translate: Formally express concepts, flow diagrams, and narrative content
• Validate: Build and run test cases to verify expected functionality

The following diagram depicts the relationship and (navigable) links between the artifacts in the CPG IG and their respective instantiations in this IG.

Data Exchange Profiles IG

The HL7 Data Exchange Profiles for 2022 CDC Clinical Practice Guideline for Prescribing Opioids has been developed to define a set of conformance requirements for supporting the data queries used in this implementation guide. By conforming to these profiles (which are derived from US Core) EHRs can ensure they are prepared to support the integration with this IG.

Trigger Overview

This implementation guide assumes that CDS Hooks serves as the technical framework for EHR integration. The table below outlines the supported triggering events for each guideline recommendation:

	patient-view	order-select	order-sign
Recommendation 1			✓
Recommendation 2			✓
Recommendation 3			✓
Recommendation 4			✓
Recommendation 5			✓
Recommendation 6			✓
Recommendation 7			✓
Recommendation 8			✓
Recommendation 9			✓
Recommendation 10	✓*		✓
Recommendation 11	✓*	✓
Recommendation 12	✓

(*) Developed for implementations without capabilities to support the preferred trigger.

Morphine Milligram Equivalent (MME) Calculation Cautions

1. All doses are in mg/day except for fentanyl, which is mcg/hr.

2. Equianalgesic dose conversions are only estimates and cannot account for individual variability in genetics and pharmacokinetics.

3. Do not use the calculated dose in MMEs to determine the doses to use when converting one opioid to another; when converting opioids, the new opioid is typically dosed at a substantially lower dose than the calculated MME dose to avoid overdose because of incomplete cross-tolerance and individual variability in opioid pharmacokinetics. Consult the FDA approved product labeling for specific guidance on medications.

4. Use particular caution with methadone dose conversions because methadone has a long and variable half-life, and peak respiratory depressant effect occurs later and lasts longer than peak analgesic effect.

5. Use particular caution with transdermal fentanyl because it is dosed in mcg/hr instead of mg/day, and its absorption is affected by heat and other factors.

6. Buprenorphine products approved for the treatment of pain are not included in the table because of their partial µ-receptor agonist activity and resultant ceiling effects compared with full µ-receptor agonists.

7. These conversion factors should not be applied to dosage decisions related to the management of opioid use disorder.

Morphine milligram equivalent doses for commonly prescribed opioids for pain management table

Opioid	Conversion Factor
Codeine	0.15
Fentanyl transdermal (in mcg/hr)	2.4
Hydrocodone	1.0
Hydromorphone	5.0
Methadone	4.7
Morphine	1.0
Oxycodone	1.5
Oxymorphone	3.0
Tapentadol *	0.4
Tramadol **	0.2

* Tapentadol is a µ-receptor agonist and norepinephrine reuptake inhibitor. MMEs are based on degree of µ-receptor agonist activity; however, it is unknown whether tapentadol is associated with overdose in the same dose-dependent manner as observed with medications that are solely µ-receptor agonists.

** Tramadol is a µ-receptor agonist and norepinephrine and serotonin reuptake inhibitor. MMEs are based on degree of µ-receptor agonist activity; however, it is unknown whether tramadol is associated with overdose in the same dose-dependent manner as observed with medications that are solely µ-receptor agonists.

Credits

Project Team

• Johnathan Coleman (Security Risk Solutions)
• Mohammad Jafari, PhD (Security Risk Solutions)
• Kensaku Kawamoto, MD, PhD, MHS (Independent)
• Robert McClure, MD (Independent)
• Amber Patel (Security Risk Solutions)
• Bryn Rhodes (Smile CDR)
• Chris Schuler (Smile CDR)
• Greg White (Security Risk Solutions)

Government Leadership

• Mera Choi (ASTP)
• Alison Kemp, MPH (ASTP)
• Anastasia Perchem (ASTP)
• Adam Wong, MPP (ASTP)

Intellectual Property

This publication includes IP covered under the following statements.

• © Copyright 2022 American Medical Association
  Show Usage
  • NUCC Provider Taxonomy: Encounter/oncologist-participant, ONCOLOGY_SPECIALTY_DESIGNATIONS and PractitionerRole/oncology-specialist
• Centers for Disease Control and Prevention (CDC)
  Show Usage
  • CDC Opioid Override Reasons: PlanDefinition_Recommendation_10_Order_Sign
• Copyright 2019+ Centers for Disease Control and Prevention (CDC)
  Show Usage
  • CDC MME Usage Context Codes: PlanDefinition_Recommendation_04_05_Order_Sign
• This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
  Show Usage
  • LOINC: ALL_URINE_DRUG_SCREENING_TESTS, AMPHETAMINE_URINE_DRUG_SCREENING_TESTS... Show 18 more, BARBITURATE_URINE_DRUG_SCREENING_TESTS, BENZODIAZEPINE_URINE_DRUG_SCREENING_TESTS, BUPRENORPHINE_URINE_DRUG_SCREENING_TESTS, CANNABINOID_URINE_DRUG_SCREENING_TESTS, COCAINE_URINE_DRUG_SCREENING_TESTS, FENTANYL_TYPE_URINE_DRUG_SCREENING_TESTS, GENERAL_OPIATE_URINE_DRUG_SCREENING_TESTS, HEROIN_URINE_DRUG_SCREENING_TESTS, METHADONE_URINE_DRUG_SCREENING_TESTS, NON_OPIOID_URINE_DRUG_SCREENING, OPIATE_SPECIFIC_URINE_DRUG_SCREENING_TESTS, OPIOID_URINE_DRUG_SCREENING, OXYCODONE_URINE_DRUG_SCREENING_TESTS, Observation/example-opioidcds, PAIN_TREATMENT_PLAN, PHENCYCLIDINE_URINE_DRUG_SCREENING_TESTS, SYNTHETIC_OPIOID_URINE_DRUG_SCREENING_TESTS and XYLAZINE_URINE_DRUG_SCREENING_TESTS
• This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org.
  Show Usage
  • SNOMED Clinical Terms® (SNOMED CT®): ActivityDefinition_Risk_Assessment_ServiceRequest, ActivityDefinition_Urine_Screening_ServiceRequest... Show 39 more, CONDITIONS_DOCUMENTING_SUBSTANCE_ABUSE, CONDITIONS_LIKELY_TERMINAL_FOR_OPIOID_PRESCRIBING, Condition/end-of-life, Condition/terminal, ConversionFactors, HOSPICE_DISPOSITION, HOSPICE_FINDING, HOSPICE_PROCEDURE, LIMITED_LIFE_EXPECTANCY_CONDITIONS, MMECalculator, MedicationRequest/example-opioidcds, OFFICE_VISIT, OMTKData, OMTKLogic, OPIOID_COUNSELING_PROCEDURE, OPIOID_MISUSE_ASSESSMENT_PROCEDURE, OPIOID_MISUSE_DISORDERS, OPIOID_TREATMENT_ASSESSMENT_PROCEDURE, PAIN_MANAGEMENT_PROCEDURE, PDMP_DATA_REVIEWED_FINDING, PDMP_REVIEW_PROCEDURE, PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View, PlanDefinition_Recommendation_12_Patient_View, SICKLE_CELL_DISEASES, SLEEP_DISORDERED_BREATHING, SUBSTANCE_MISUSE_BEHAVIORAL_COUNSELING, ServiceRequest/palliative-care and THERAPIES_INDICATING_END_OF_LIFE_CARE
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
  Show Usage
  • ActionType: PlanDefinition_Recommendation_07_Order_Sign and PlanDefinition_Recommendation_10_Patient_View
  • Condition Category Codes: Condition/cancer-diagnosis, Condition/terminal, ENCOUNTER_DIAGNOSIS_CONDITION_CATEGORY and PROBLEM_LIST_CONDITION_CATEGORY
  • Condition Clinical Status Codes: CONDITION_CLINICAL_STATUS_ACTIVE, Condition/cancer-diagnosis, Condition/end-of-life and Condition/terminal
  • DefinitionTopic: ActivityDefinition_Risk_Assessment_ServiceRequest and ActivityDefinition_Urine_Screening_ServiceRequest
  • DoseAndRateType: MedicationRequest/example-opioidcds
  • QualityOfEvidenceRating: PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign... Show 11 more, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View and PlanDefinition_Recommendation_12_Patient_View
  • LibraryType: CDCMMEClinicalConversionFactors, ConversionFactors... Show 39 more, FHIR, FHIRHelpers, HelloWorld, HelloWorldPatientView, MMECalculator, OMTKData, OMTKData2020, OMTKLogic, OMTKLogicMK2020, OpioidCDSCommon, OpioidCDSCommonConfig, OpioidCDSREC01, OpioidCDSREC02, OpioidCDSREC03, OpioidCDSREC04And05, OpioidCDSREC06, OpioidCDSREC07, OpioidCDSREC08, OpioidCDSREC09, OpioidCDSREC10Common, OpioidCDSREC10OrderSign, OpioidCDSREC10PatientView, OpioidCDSREC11OrderSelect, OpioidCDSREC11PatientView, OpioidCDSREC12PatientView, OpioidCDSRoutines, PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View and PlanDefinition_Recommendation_12_Patient_View
  • MedicationRequest Category Codes: MedicationRequest/ambulatory-opioid and Valueset_medicationrequest_category_community
  • Observation Category Codes: OBSERVATION_CATEGORY_LABORATORY and OBSERVATION_CATEGORY_PROCEDURE
  • PlanDefinitionType: PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign... Show 11 more, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View and PlanDefinition_Recommendation_12_Patient_View
  • StrengthOfRecommendationRating: PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign... Show 11 more, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View and PlanDefinition_Recommendation_12_Patient_View
  • Software System Type Codes: Device/cqf-tooling
  • UsageContextType: ActivityDefinition_Risk_Assessment_ServiceRequest, ActivityDefinition_Urine_Screening_ServiceRequest... Show 17 more, ConversionFactors, MMECalculator, OMTKData, OMTKLogic, PlanDefinition_Recommendation_01_Order_Sign, PlanDefinition_Recommendation_02_Order_Sign, PlanDefinition_Recommendation_03_Order_Sign, PlanDefinition_Recommendation_04_05_Order_Sign, PlanDefinition_Recommendation_06_Order_Sign, PlanDefinition_Recommendation_07_Order_Sign, PlanDefinition_Recommendation_08_Order_Sign, PlanDefinition_Recommendation_09_Order_Sign, PlanDefinition_Recommendation_10_Order_Sign, PlanDefinition_Recommendation_10_Patient_View, PlanDefinition_Recommendation_11_Order_Select, PlanDefinition_Recommendation_11_Patient_View and PlanDefinition_Recommendation_12_Patient_View
  • ActCode: Encounter/cancer-diagnosis and Encounter/oncologist-participant
  • ObservationInterpretation: Observation/example-opioidcds
• Used by permission of HL7 International, all rights reserved Creative Commons License
  Show Usage
  • US Core Condition Category Extension Codes: Condition/end-of-life and US_CORE_HEALTH_CONCERN_CONDITION_CATEGORY
• Using RxNorm codes of type SAB=RXNORM as this specification describes does not require a UMLS license. Access to the full set of RxNorm definitions, and/or additional use of other RxNorm structures and information requires a UMLS license. The use of RxNorm in this specification is pursuant to HL7's status as a licensee of the NLM UMLS. HL7's license does not convey the right to use RxNorm to any users of this specification; implementers must acquire a license to use RxNorm in their own right.
  Show Usage
  • RxNorm: AMPHETAMINES_CLASS_MEDICATIONS, BARBITURATE_MEDICATIONS... Show 15 more, BENZODIAZEPINE_MEDICATIONS, BUPRENORPHINE_AND_METHADONE_MEDICATIONS, BUPRENORPHINE_MEDICATIONS, CNS_DEPRESSANT_MEDICATIONS, EXTENDED_RELEASE_OPIOID_WITH_AMBULATORY_MISUSE_POTENTIAL, FENTANYL_TYPE_MEDICATIONS, METHADONE_MEDICATIONS, MedicationDispense/ambulatory-opioid, MedicationRequest/ambulatory-opioid, MedicationRequest/example-opioidcds, NALOXONE_MEDICATIONS, NON_SYNTHETIC_OPIOID_MEDICATIONS, OPIOID_ANALGESICS_WITH_AMBULATORY_MISUSE_POTENTIAL, OXYCODONE_MEDICATIONS and SYNTHETIC_OPIOID_MEDICATIONS

Cross Version Analysis

This is an R4 IG. None of the features it uses are changed in R4B, so it can be used as is with R4B systems. Packages for both R4 (fhir.cdc.opioid-cds-r4.r4) and R4B (fhir.cdc.opioid-cds-r4.r4b) are available.

Dependencies

Package hl7.fhir.uv.extensions.r4#5.2.0 This IG defines the global extensions - the ones defined for everyone. These extensions are always in scope wherever FHIR is being used (built Mon, Feb 10, 2025 21:45+1100+11:00)

Package hl7.fhir.uv.cpg#1.0.0 Implementation guidance for creating Clinical Practice Guidelines with formal artifacts to facilitate sharing and implementation of the guideline (built Thu, Feb 11, 2021 20:29+0000+00:00)

Package fhir.cqf.common#4.0.1 This implementation guide contains common FHIR assets for use in CQFramework content IGs, including FHIRHelpers and the FHIR-ModelInfo libraries. (built Fri, Nov 12, 2021 16:25+1100+11:00)

Package fhir.cdc.opioid-mme-r4#3.0.0 Opioid Morphine Milligram Equivalent (MME) calculation logic in FHIR and Clinical Quality Language (CQL) (built Thu, Nov 25, 2021 15:13+1100+11:00)

Package hl7.fhir.uv.extensions.r4#1.0.0 This IG defines the global extensions - the ones defined for everyone. These extensions are always in scope wherever FHIR is being used (built Sun, Mar 26, 2023 08:46+1100+11:00)

Package hl7.fhir.uv.extensions.r4#5.1.0 This IG defines the global extensions - the ones defined for everyone. These extensions are always in scope wherever FHIR is being used (built Sat, Apr 27, 2024 18:39+1000+10:00)

Package hl7.fhir.uv.crmi#1.0.0 This implementation guide defines profiles, operations, capability statements and guidance to facilitate the content management lifecycle for authoring, publishing, distribution, and implementation of FHIR knowledge artifacts such as value sets, profiles, libraries, rules, and measures. The guide is intended to be used by specification and content implementation guide authors as both a dependency for validation of published artifacts, and a guide for construction and publication of content. (built Fri, May 31, 2024 16:38+0000+00:00)

Package hl7.fhir.uv.tools.r4#0.9.0 This IG defines the extensions that the tools use internally. Some of these extensions are content that are being evaluated for elevation into the main spec, and others are tooling concerns (built Tue, Dec 16, 2025 23:18+1100+11:00)

Globals

There are no Global profiles defined

Expansion Parameters

Parameter	Value
system-version	SNOMED CT[US rel. Oct 0012]
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-computablevalueset|1.0.0
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-executablevalueset|1.0.0
system-version	International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)[2.0.1]
system-version	NUCC Provider Taxonomy[4.0.0]
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-shareablelibrary|1.0.0
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-computablelibrary|1.0.0
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-publishablelibrary|1.0.0
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-executablelibrary|1.0.0
system-version	UsageContextType[2.0.1]
system-version	CDC MME Usage Context Codes[3.0.0]
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Patient|4.0.1
system-version	RxNorm[3.0.1]
system-version	LOINC[3.1.0]
default-valueset-version	limited-life-expectancy-conditions[2022.1.0]
default-valueset-version	therapies-indicating-end-of-life-care[2022.1.0]
default-valueset-version	conditions-likely-terminal-for-opioid-prescribing[2022.1.0]
default-valueset-version	cdc-malignant-cancer-conditions[2022.1.0]
default-valueset-version	oncology-specialty-designations[2022.1.0]
default-valueset-version	opioid-misuse-disorders[2022.1.0]
default-valueset-version	substance-misuse-behavioral-counseling[2022.1.0]
default-valueset-version	conditions-documenting-substance-misuse[2022.1.0]
default-valueset-version	office-visit[0.2.0]
default-valueset-version	opioid-counseling-procedure[2022.1.0]
default-valueset-version	opioid-misuse-assessment-procedure[2022.1.0]
default-valueset-version	hospice-disposition[2022.1.0]
default-valueset-version	hospice-finding[2022.1.0]
default-valueset-version	observation-category-laboratory[2022.1.0]
default-valueset-version	observation-category-procedure[2022.1.0]
default-valueset-version	pain-treatment-plan[2022.1.0]
default-valueset-version	pain-management-procedure[2022.1.0]
default-valueset-version	pdmp-review-procedure[2022.1.0]
default-valueset-version	pdmp-data-reviewed-finding[2022.1.0]
default-valueset-version	conditions-documenting-sleep-disordered-breathing[2022.1.0]
default-valueset-version	opioid-analgesics-with-ambulatory-misuse-potential[2022.1.0]
default-valueset-version	extended-release-opioid-with-ambulatory-misuse-potential[2022.1.0]
default-valueset-version	buprenorphine-medications[2022.1.0]
default-valueset-version	buprenorphine-and-methadone-medications[2022.1.0]
default-valueset-version	non-synthetic-opioid-medications[2022.1.0]
default-valueset-version	barbiturate-medications[2022.1.0]
default-valueset-version	benzodiazepine-medications[2022.1.0]
default-valueset-version	naloxone-medications[2022.1.0]
default-valueset-version	fentanyl-type-medications[2022.1.0]
default-valueset-version	amphetamines-class-medications[2022.1.0]
default-valueset-version	methadone-medications[2022.1.0]
default-valueset-version	oxycodone-medications[2022.1.0]
default-valueset-version	synthetic-opioid-medications[2022.1.0]
default-valueset-version	cns-depressant-medications[2022.1.0]
default-valueset-version	all-urine-drug-screening-tests[2022.1.0]
default-valueset-version	non-opioid-urine-drug-screening[2022.1.0]
default-valueset-version	opiate-specific-urine-drug-screening-tests[2022.1.0]
default-valueset-version	general-opiate-urine-drug-screening-tests[2022.1.0]
default-valueset-version	opioid-urine-drug-screening[2022.1.0]
default-valueset-version	cocaine-urine-drug-screening-tests[2022.1.0]
default-valueset-version	phencyclidine-urine-drug-screening-tests[2022.1.0]
default-valueset-version	fentanyl-type-urine-drug-screening-tests[2022.1.0]
default-valueset-version	amphetamine-urine-drug-screening-tests[2022.1.0]
default-valueset-version	cannabinoid-urine-drug-screening-tests[2022.1.0]
default-valueset-version	methadone-urine-drug-screening-tests[2022.1.0]
default-valueset-version	synthetic-opioid-urine-drug-screening-tests[2022.1.0]
default-valueset-version	barbiturate-urine-drug-screening-tests[2022.1.0]
default-valueset-version	benzodiazepine-urine-drug-screening-tests[2022.1.0]
default-valueset-version	buprenorphine-urine-drug-screening-tests[2022.1.0]
default-valueset-version	heroin-urine-drug-screening-tests[2022.1.0]
default-valueset-version	oxycodone-urine-drug-screening-tests[2022.1.0]
default-valueset-version	medicationrequest-category-community[0.0.1]
default-valueset-version	condition-clinical-status-active[2022.1.0]
default-valueset-version	medicationrequest-status-active[0.0.1]
default-valueset-version	condition-encounter-diagnosis-category[2022.1.0]
default-valueset-version	condition-problem-list-category[2022.1.0]
default-valueset-version	condition-us-core-health-concern-category[2022.1.0]
default-valueset-version	sickle-cell-diseases[2022.1.0]
default-canonical-version	http://hl7.org/fhir/StructureDefinition/MedicationRequest|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Medication|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Condition|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Observation|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Encounter|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/CarePlan|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/Procedure|4.0.1
default-canonical-version	http://hl7.org/fhir/StructureDefinition/MedicationDispense|4.0.1
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-recommendationdefinition|1.0.0
default-canonical-version	http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-publishableplandefinition|1.0.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC01|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC02|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC03|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC04And05|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC06|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC07|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/ActivityDefinition/opioidcds-risk-assessment-request|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC08|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC09|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC10OrderSign|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC10PatientView|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/ActivityDefinition/opioidcds-urine-screening-request|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC11OrderSelect|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC11PatientView|2022.1.0
default-canonical-version	http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC12PatientView|2022.1.0